SST2-POSITIVE NEUROENDOCRINE NEOPLASMS

Clinical trials for SST2-POSITIVE NEUROENDOCRINE NEOPLASMS explained in plain language.

Never miss a new study

Get alerted when new SST2-POSITIVE NEUROENDOCRINE NEOPLASMS trials appear

Sign up with your email to follow new studies for SST2-POSITIVE NEUROENDOCRINE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New weapon tested against rare, Hard-to-Treat cancers

Disease control Recruiting now

This early-stage clinical trial is testing a new drug called CRN09682 for people with advanced neuroendocrine tumors and other solid tumors that have a specific marker (SST2). The main goals are to find a safe and tolerable dose and to see if the drug shows early signs of helping…

Matched conditions: SST2-POSITIVE NEUROENDOCRINE NEOPLASMS

Phase: PHASE1, PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

SST2-POSITIVE NEUROENDOCRINE NEOPLASMS

Get alerted when new SST2-POSITIVE NEUROENDOCRINE NEOPLASMS trials appear

New weapon tested against rare, Hard-to-Treat cancers